Roche Holding AG (OTCMKTS:RHHBY) Receives $51.50 Consensus Price Target from Analysts

Posted by on May 21st, 2026

Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) has been given a consensus recommendation of “Hold” by the eleven ratings firms that are covering the company, Marketbeat reports. Six analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $51.50.

RHHBY has been the topic of a number of research reports. TD Cowen reaffirmed a “hold” rating on shares of Roche in a research report on Tuesday, February 10th. Argus raised Roche from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Wolfe Research reaffirmed an “outperform” rating on shares of Roche in a research report on Thursday, February 26th. Morgan Stanley raised Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 target price on the stock in a research report on Friday, April 24th. Finally, Citigroup initiated coverage on Roche in a research report on Tuesday, January 27th. They set a “buy” rating on the stock.

Check Out Our Latest Stock Report on RHHBY

Roche Price Performance

Roche stock opened at $51.94 on Friday. Roche has a 52-week low of $37.51 and a 52-week high of $60.85. The stock’s 50 day moving average price is $50.51 and its two-hundred day moving average price is $51.62. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38.

Hedge Funds Weigh In On Roche

A number of institutional investors have recently modified their holdings of RHHBY. Curio Wealth LLC acquired a new position in shares of Roche during the third quarter worth approximately $25,000. McIlrath & Eck LLC purchased a new stake in Roche in the 1st quarter valued at $39,000. Oakworth Capital Inc. purchased a new stake in Roche in the 3rd quarter valued at $57,000. Atlas Capital Advisors Inc. purchased a new stake in Roche in the 4th quarter valued at $192,000. Finally, Douglass Winthrop Advisors LLC purchased a new stake in Roche in the 3rd quarter valued at $201,000.

About Roche

(Get Free Report)

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

Featured Stories

Analyst Recommendations for Roche (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.